SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals (SNDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is trading at pre-market levels of $24.84, which is within the valuation range analysts have highlighted. Despite recent insider and hedge fund selling, the company's strong revenue growth, bullish technical indicators, and upcoming Phase 2 MAXPIRe data release in Q4 provide a compelling long-term growth opportunity.
The technical indicators are bullish. The MACD is positive and expanding, RSI is neutral at 74.595, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 24.203, with resistance at 25.193 and 25.804, suggesting potential upside in the near term.
Analysts have raised price targets significantly, with JPMorgan seeing a potential value in the high-$20s to low-$30s per share range and Citi targeting $
The upcoming Phase 2 MAXPIRe data release for Niktimvo in Q4 could act as a major catalyst.
Revenue growth of 794.90% YoY in Q4 2025 highlights strong operational performance.
Insider and hedge fund selling activity, including significant reductions by DAFNA Capital and Kynam Capital.
Net income and EPS have declined YoY, indicating profitability challenges.
No recent congress trading data or AI trading signals to support immediate action.
In Q4 2025, revenue increased by 794.90% YoY to $68.73 million, showcasing strong growth. However, net income dropped by 27.77% YoY to -$68.01 million, and EPS declined by 28.44% YoY to -0.78, reflecting ongoing losses. Gross margin improved to 96.06%, up 7.64% YoY, indicating operational efficiency.
Analysts are bullish on SNDX, with JPMorgan, Citi, and BofA raising price targets recently. JPMorgan sees the current share price as undervalued, with potential upside from the Niktimvo IPF opportunity. Citi's price target of $57 reflects strong confidence in the stock's long-term potential.
